Antigenically Distinct MF59-Adjuvanted Vaccine to Boost Immunity to H5N1
- 9 October 2008
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 359 (15) , 1631-1633
- https://doi.org/10.1056/nejmc0805274
Abstract
Antigenically distinct avian influenza A (H5N1) viruses are widely dispersed.1 Clade 1 H5N1 viruses previously predominated in Indochina. Indonesian, Eurasian, and African viruses are clustered in a clade 2 group, with antigenically distinct sublineages. Clade 0 viruses caused influenza outbreaks in Hong Kong in 1997 but have not been isolated since then. To reduce shortfalls in vaccine supply at the onset of the next pandemic, advance stockpiling of vaccine has been suggested. Because of antigenic evolution of H5N1, current vaccines may be suboptimally matched to the actual pandemic virus. Proactive priming may induce immune memory, allowing low-dose vaccination to induce rapid cross-protection when needed.Keywords
This publication has 5 references indexed in Scilit:
- Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult VolunteersJournal of Virology, 2006
- Strategies for mitigating an influenza pandemicNature, 2006
- Establishment of multiple sublineages of H5N1 influenza virus in Asia: Implications for pandemic controlProceedings of the National Academy of Sciences, 2006
- Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human populationVaccine, 2002
- Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenzaThe Lancet, 2001